FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1414-1415 May 2, 2002 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Noda and colleagues (Jan. 10 issue)¹ report that the combination of irinotecan plus cisplatin is superior to etoposide plus cisplatin for extensive small-cell lung cancer. The dose of irinotecan was based on the patient's body-surface area.

Irinotecan is a prodrug that is metabolized in vivo, forming active 7-ethyl-10-hydroxycamptothecin (SN-38). SN-38 is further conjugated and detoxified by a polymorphic UGT1A1 enzyme, yielding its glucuronide. We have shown that there is a statistically significant association between the presence of the variant UGT1A1*28 allele and severe irinotecan toxicity.² In particular, there were severe toxic effects in all the patients carrying . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.